Showing 4681-4690 of 9847 results for "".
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to
- New Interim CEO Named For Canada's Crescitahttps://practicaldermatology.com/news/new-interim-ceo-for-canadas-crescita/2458386/Dan Chicoine is now the interim Chief Executive Officer of Crescita Therapeutics Inc., a commercial dermatology company in Canada. He is replacing Greg Orleski. Mr. Chicoine will also continue to serve as the Company's Executive
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Allergan's New #ActuallySheCan Campaign Aims to Inspire Young Womenhttps://practicaldermatology.com/news/allergans-new-actuallyshecan-campaign-aims-to-inspire-young-women/2458407/Allergan’s new female empowerment campaign ActuallySheCanSM provides young women with inspirational advice and stresses the importance of female mentorship. The campaign includes portraits of actress Chloë Grace Mor
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.